Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 …
Posted: April 20, 2012 at 11:10 am
SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus Associated Kinase 2) selective inhibitor that has demonstrated encouraging clinical benefit in phase 1 and 2 clinical studies in patients with primary myelofibrosis (MF) or MF secondary to other myeloproliferative neoplasms (MPN). Pacritinib has orphan drug designation in the U.S. and Europe for myelofibrosis.
"JAK2 dysregulation is associated with a broad range of difficult-to-treat illnesses, including cancers and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today," said James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe a highly selective JAK2 inhibitor that also inhibits the JAK2 clonal mutation (JAK2V617F) offers a distinct biological and clinical advantage over marketed or development stage compounds which are non-selective inhibitors of the JAK pathway. We believe that the lack of suppression of red blood cell and platelet formation seen with pacritinib has the potential to satisfy a medical need not currently addressed with existing non-selective JAK1/JAK2 inhibitors."
"The acquisition of pacritinib is aligned with our strategy of becoming a leader in the treatment of blood related cancers and disorders. We are looking forward to build on the progress made by S*BIO," Bianco continued. "With Pixuvri approaching approval and launch in the EU, and tosedostat and pacritinib entering phase 3 our late stage portfolio addresses a full complement of blood related cancers ranging from MPN to MDS, leukemia and lymphoma."
"JAK inhibitors are a very exciting new class of targeted agents that provide effective treatment in a previously difficult to treat disease called myelofibrosis," stated Srdan Verstovsek, M.D., Ph.D., Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas and Executive Committee Member, International Working Group for Myelofibrosis. "Pacritinib is a highly specific JAK2 inhibitor that does not appear to cause suppression of platelets or red blood cells as seen with other treatments, while reducing enlarged spleen and improving disease related debilitating symptoms in patients with myelofibrosis. I am looking forward to working with Cell Therapeutics in developing this agent for patients with myelofibrosis who present with low blood counts or develop them on therapy."
"We are most impressed with CTI's experienced team and believe that they are the ideal company to further develop pacritinib, S*BIO's most advanced program," commented Ms. Tamar Howson, S*BIO's CEO. S*BIO is a privately-held biotechnology company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI, Aravis Ventures, Mitsui Ventures and other international funds.
Pursuant to the terms of the agreement, CTI will make an upfront payment of $15 million and issue $15 million shares of unregistered preferred stock convertible into common stock in CTI. The agreement also includes regulatory success- and sales-based milestone payments, as well as single digit royalties on net sales. CTI will be solely responsible for development and commercialization activities of pacritinib worldwide. The agreement will be subject to satisfaction of certain closing conditions. The terms of the agreement will be provided in more detail in a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
About Janus Associated Kinase (JAK)
The JAK family of enzymes are a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. When dysregulated by activating mutations, uncontrolled blood cell growth can occur accompanied by inflammation and immune system activation contributing to disease manifestations in MPN. Autoimmune diseases such as psoriasis and rheumatoid arthritis also have activation of this pathway and JAK inhibitors are in development for these disorders. In addition, activation of the JAK2 pathway and the related FLT3 pathway (whether by activating mutations or other causes) is frequently associated with leukemia, and lymphoma. Pacritinib inhibits both JAK2 and FLT3 suggesting potential use in treating such blood related cancers.
Myelofibrosis is a stem cell-derived clonal myeloproliferative disease frequently associated with a mutation in the JAK2 gene (JAK2V617F). Inhibition of JAK1/ JAK2 has recently been shown to lead to clinical benefit in patients with advanced MF and platelet counts of 100,000 or higher at study entry, resulting in the first JAK1/JAK2 inhibitor to be approved for patients with advanced MF. The approved JAK inhibitor is not selective for JAK2 but inhibits both JAK1 and JAK2. While effective in reducing patients symptoms associated with MF, JAK1/JAK2 inhibitors frequently cause suppression of platelets and red blood cells, often leading to a need for red blood cell transfusions. Pacritinib may offer an advantage over other JAK inhibitors by having less bone marrow suppression. Such agents may also lead to a modification of the underlying disease process by selectively affecting the malignant clone expressing JAK2V617F.
About Myeloproliferative Neoplasms (MPN)
Original post:
Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 ...
- Eli and Edythe Broad Center of Regeneration Medicine and ... - October 30th, 2015
- Molecular & Cellular Medicine - October 29th, 2015
- Sickle cell anemia Treatments and drugs - Mayo Clinic - October 29th, 2015
- How are stem cells used in medicine today? - HowStuffWorks - October 29th, 2015
- Oxidative Medicine and Cellular Longevity An Open Access ... - October 29th, 2015
- Department of Regenerative Medicine and Cell Biology - October 29th, 2015
- Sickle Cell Anemia: MedlinePlus - National Library of Medicine - October 29th, 2015
- Personalized RegenerativeMedicine : Dr David Steenblock - October 29th, 2015
- Cell Therapy and Regenerative Medicine - October 29th, 2015
- The Power of Stem Cells | California's Stem Cell Agency - October 29th, 2015
- Herbal medicine | Cancer Research UK - October 29th, 2015
- UR Stem Cell and Regenerative Medicine Institute (SCRMI) - October 29th, 2015
- Penn Medicine News: Genetically Modified "Serial Killer" T ... - October 29th, 2015
- Beta cell regeneration - Center for Regenerative Medicine ... - October 29th, 2015
- The Stem Cell Theory of Cancer - Stanford Medicine Center - October 29th, 2015
- What is a cell? - Genetics Home Reference - October 16th, 2015
- Cell Therapy & Regenerative Medicine - University of Utah ... - October 13th, 2015
- Sickle Cell Anemia: Learn About SCD Symptoms and Treatment - September 26th, 2015
- Research - Stem Cell Biology and Regenerative Medicine ... - September 26th, 2015
- Sickle Cell Disease (Sickle Cell Anemia ... - MedicineNet - September 26th, 2015
- T Cell Therapy (CTL019) | The Children's Hospital of ... - September 15th, 2015
- Knoepfler Lab Stem Cell Blog | Building innovative ... - September 10th, 2015
- Cell culture - Wikipedia, the free encyclopedia - September 6th, 2015
- What are the potential uses of human stem cells and the ... - August 17th, 2015
- One type of airway cell can regenerate another lung cell type - April 13th, 2015
- Limber Lungs: One Type of Airway Cell Can Regenerate Another Lung Cell Type - April 13th, 2015
- Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015 - April 6th, 2015
- 'Open' stem cell chromosomes reveal new possibilities for diabetes - April 3rd, 2015
- Key mechanism identified in tumor-cell proliferation in pediatric bone cancers - April 3rd, 2015
- UCI team gets $5 million to create stem cell treatment for Huntington's disease - March 28th, 2015
- Sungduan: Growth factors - March 28th, 2015
- Cleveland Clinic Researchers First to Demonstrate Significant Blocking of Opioid Tolerance With Mesenchymal Stem Cell ... - March 25th, 2015
- Johns Hopkins Medicine, based in Baltimore, Maryland - March 23rd, 2015
- stem cell medicine Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- Global Stem Cells Group to Hold Practical Adipose-Derived Stem Cell Harvesting, Isolation and Re-integration Training ... - March 20th, 2015
- Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at ... - March 18th, 2015
- A Single-Cell Breakthrough: newly developed technology dissects properties of single stem cells - March 18th, 2015
- BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York - March 18th, 2015
- Global Stem Cells Group to Participate in the 25th Argentine Congress of Aesthetic Medicine in Buenos Aires April 9-10 ... - March 17th, 2015
- Boosting A Natural Protection Against Alzheimer's Disease - March 13th, 2015
- Media portray unrealistic timelines for stem cell therapies - March 12th, 2015
- Stem cells lurking in tumors can resist treatment - March 12th, 2015
- Building custom blood cells to battle sickle cell disease - March 11th, 2015
- Johns Hopkins researchers engineer custom blood cells - March 10th, 2015
- Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the ... - March 10th, 2015
- Mast cell - Wikipedia, the free encyclopedia - March 9th, 2015
- Achieving gender equality in science, engineering and medicine - March 9th, 2015
- Seven strategies to advance women in science - March 9th, 2015
- British biotech firm sets crowdfunding record with heart drug - March 9th, 2015
- A good night's sleep keeps your stem cells young - March 9th, 2015
- Howe's recovery shows stem-cell advances - March 1st, 2015
- Translational Regenerative Medicine: Market Prospects 2015-2025 - February 28th, 2015
- Stem cellrecruiting hydrogels based on self-assembling peptides for tissue regeneration - February 25th, 2015
- Sertoli cell - Wikipedia, the free encyclopedia - February 17th, 2015
- Global Stem Cells Group Announces Alliance with Regenerative Technology - February 11th, 2015
- Biotech firm Cell Therapy claims crowdfunding record with heart drug - February 10th, 2015
- Two UC San Diego Scientists Receive Stem Cell Technology Grants - February 3rd, 2015
- Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan - January 31st, 2015
- Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ... - January 29th, 2015
- Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ... - January 29th, 2015
- Gordie Howe's stem cell therapy raises concerns among medical experts - January 29th, 2015
- Gordie Howe's stem cell therapy raises concerns among experts - January 29th, 2015
- BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer ... - January 27th, 2015
- Keeping the Kraken asleep - January 27th, 2015
- Helmholtz International Fellow Award for Prof. Amanda Fisher from London - January 27th, 2015
- Regenestem Network, a division of Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative ... - January 22nd, 2015
- Scientists announce revolutionary culturing technique for liver and pancreas - January 22nd, 2015
- New Type of Cell Found to Repair Lung Injury in Mice - January 18th, 2015
- Stem cells derived from amniotic tissues have immunosuppressive properties - January 16th, 2015
- Global Stem Cells Group to Move Headquarters to Larger Miami Lakes Office Complex - January 14th, 2015
- Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford - January 13th, 2015
- Renowned professor's book addresses stem cell biology & regenerative medicine - January 13th, 2015
- Circadian rhythms regulate skin stem cell metabolism and expansion, study finds - January 7th, 2015
- Cord Blood Banking Leader, Cryo-Cell International, Continues to Support the Advancement of Regenerative Medicine - January 6th, 2015
- Scientists Develop Pioneering Method to Define Stages of Stem Cell Reprogramming - January 6th, 2015
- Pioneering method developed to define stages of stem cell reprogramming - January 6th, 2015
- The Irvine Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Orange County, California - January 5th, 2015
- Ten years in, California's stem cell program is getting a reboot - January 4th, 2015
- Two-thirds of cancer cases are "bad luck," study says - January 1st, 2015
- 'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows - January 1st, 2015